TEXT OF STORY
JEREMY HOBSON: The FDA says the world’s best selling cancer medication can’t be used to treat breast cancer. The drug is called Avastin. And it’s made by the pharmaceutical company Roche.
Marketplace’s Janet Babin reports.
JANET BABIN: Avastin brings in about $6 billion a year for Roche; the FDA’s move could cut $1 billion in sales. The FDA said Avastin didn’t extend patient survival and was accompanied by serious side effects. Dr. Hyman Muss at the University of North Carolina says in his experience, those side effects are manageable. He says the FDA’s unusual decision might have something to do with the cost.
HYMAN MUSS: Insurers, medicare reimbursing for the cost of the drug — it’s certainly the cost of healthcare.
Roche says it will appeal the FDA decision. Until that hearing, Avastin remains FDA approved for breast cancer.
In New York, I’m Janet Babin for Marketplace.
Marketplace is on a mission.
We believe Main Street matters as much as Wall Street, economic news is made relevant and real through human stories, and a touch of humor helps enliven topics you might typically find…well, dull.
Through the signature style that only Marketplace can deliver, we’re on a mission to raise the economic intelligence of the country—but we don’t do it alone. We count on listeners and readers like you to keep this public service free and accessible to all. Will you become a partner in our mission today?